Condition

NSCLC Stage IIIB

ClinicalTrials.gov condition label

Clinical trials22

Recruiting2

Common interventions25

Lead sponsors shown15

Clinical trials

22 shown

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)NCT05281406 · 2021-11-12

Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLCNCT04865250 · 2021-01-07

Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE TrialNCT07746388 · 2026-09-01

NOT_YET_RECRUITING

Exercise in Patients With Advanced Non-small Cell Lung CancerNCT06374160 · 2024-05-01

A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCCNCT05212922 · 2023-06-01

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung CancerNCT05652868 · 2023-03-23

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)NCT05816499 · 2023-02-16

Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung CancerNCT05132218 · 2021-10-19

Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line ImmunotherapyNCT04467801 · 2021-09-14

Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic TumorNCT04932343 · 2021-06-01

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLCNCT04768491 · 2020-09-01

Immunonutrition to Reduce Toxicities in Non-Small Cell Lung CancerNCT03628144 · 2020-07-01

Clinical Utility of Liquid Biopsy in Brigatinib ALK+ PatientsNCT04223596 · 2020-05-04

ACTIVE_NOT_RECRUITING

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted TherapiesNCT04042558 · 2019-09-26

Phase 2 Study of Dacomitinib in NSCLCNCT04027647 · 2019-09-11

ACTIVE_NOT_RECRUITING

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene FusionsNCT03805841 · 2019-03-13

1st Line Durvalumab in PS 2 NSCLC PatientsNCT03620669 · 2018-12-04

ACTIVE_NOT_RECRUITING

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase InhibitorsNCT03647956 · 2018-10-01

Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory StudyNCT03594682 · 2018-08-01

Phase I Study of SPH1188-11 in NSCLCNCT03231475 · 2017-07-21

Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung CancerNCT03515252 · 2005-04-26

Chemoradiotherapy of NSCLC Stage IIIBNCT00198432 · 2002-03-01

Common interventions

Leading sponsors

Beijing Chest Hospital1 Centre Francois Baclesse1 Eucure (Beijing) Biopharma Co., Ltd1 Fundación GECP1 Goethe University1 H. Lee Moffitt Cancer Center and Research Institute1 Intergroupe Francophone de Cancerologie Thoracique1 Ivy Life Sciences, Co., Ltd1 Jun Zhang, MD, PhD1 Mythic Therapeutics1 National Cancer Centre, Singapore1 Peking Union Medical College1 Peking University Cancer Hospital & Institute1 Rain Oncology Inc1 Samsung Medical Center1

Trial status mix

UNKNOWN8

ACTIVE_NOT_RECRUITING3

COMPLETED3

WITHDRAWN3

RECRUITING2

TERMINATED2

NOT_YET_RECRUITING1

Phase mix

PHASE214

PHASE14

NA2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.